©2019 by Occuity. All rights reserved.

 

Occuity specialises in the research, design and production of non-contacting optical instruments for use in healthcare diagnostics and monitoring. Occuity’s meters work by shining light into the eye and analysing the return signal. This enables direct measurements of the eye for optometrists and ophthalmologists but also, and perhaps more importantly, other more general health conditions such as diabetes and Alzheimer’s Disease to be monitored.

 

Occuity's Intellectual Property includes 9 international patents covering the measurement technique and optical technology that forms the basis of the devices along with additional patents relating to the alignment and measurements within the eye.

 

Occuity's mission is to create a range of non-contact, handheld devices which by their nature will be useable in a non-clinical setting by healthcare professionals and also personal monitoring devices for diseases such as diabetes.

TheBlade_edited_edited.jpg

Contact Us

Occuity  Ltd,

3rd Floor, The Blade,

Abbey Square 

Reading, RG1 3BE, UK

(44) 01183 500 800

Upcoming Events
Optrafair 20/20
Sat, Sep 19
Optrafair 20/20, NEC
Sep 19, 9:00 AM – Sep 21, 5:00 PM
Optrafair 20/20, NEC, North Ave, Marston Green, Birmingham B40 1NT, UK
Please note that due to COVID-19, Optrafair 2020 has been postponed from April 4-6 to September 19-21 2020. Come and see us with our new optical handheld non-contacting pachymeter on stand G34 at the NEC Birmingham
Share
Additional Investor presentation and briefing
Mon, Mar 30
3rd Floor, The Blade
Mar 30, 3:00 PM – 6:00 PM GMT+1
3rd Floor, The Blade, The Blade, Abbey Square, Reading RG1 3BE, UK
Occuity will be presenting to new and existing investors their progress on the new optical pachymeter device and outlining their plans fo the next quarter/
Share
Investor presentation and briefing
Thu, Feb 13
3rd Floor, The Blade
Feb 13, 2:00 PM – 4:30 PM GMT
3rd Floor, The Blade, The Blade, Abbey Square, Reading RG1 3BE, UK
Occuity will be presenting to new and existing investors their progress on the new optical pachymeter device and outlining their plans fo the next quarter/
Share
Occuity News